{"id":1572,"date":"2010-06-30T15:21:08","date_gmt":"2010-06-30T19:21:08","guid":{"rendered":"http:\/\/blogs.nejm.org\/cardioexchange\/%e2%80%a2responding-to-the-news%e2%80%a2retinopathy-in-accord\/"},"modified":"2011-07-19T17:44:56","modified_gmt":"2011-07-19T21:44:56","slug":"%e2%80%a2responding-to-the-news%e2%80%a2retinopathy-in-accord","status":"publish","type":"post","link":"https:\/\/blogs.nejm.org\/cardioexchange\/2010\/06\/30\/%e2%80%a2responding-to-the-news%e2%80%a2retinopathy-in-accord\/","title":{"rendered":"\u2022\u00a0Responding to the News<br \/>\u2022 Retinopathy in ACCORD"},"content":{"rendered":"<p><strong><\/strong><\/p>\n<p><strong>Responding to the News:<\/strong> It&#8217;s been an extraordinary week for cardiology news, with major papers and controversies about rosiglitazone, statins, JUPITER, and clopidogrel. Here are a few statements and news reports that you might want to know about:&nbsp;<\/p>\n<p>    <a href=\"http:\/\/www.newsroom.heart.org\/index.php?s=43&amp;item=1063\">ACC\/AHA release clinical alert in response to FDA boxed warning about anti-platelet agent, clopidogrel<\/a>&nbsp;(ACC\/AHA)<a href=\"http:\/\/www.newsroom.heart.org\/index.php?s=43&amp;item=1063\"><br \/>\n    <\/a><br \/>\n    <a href=\"http:\/\/www.newsroom.heart.org\/index.php?s=43&amp;item=1064\">New analyses report different outcomes in use of thiazolidinedione (TZD) drugs for diabetes patients<\/a>&nbsp;(AHA)<br \/>\n    <a href=\"http:\/\/newsroom.lilly.com\/releasedetail.cfm?ReleaseID=483161\">Daiichi Sankyo\/Lilly respond to ACCF\/AHA clinical alert on antiplatelet therapy<\/a>&nbsp;(Daiichi Sankyo\/Lilly)<br \/>\n    <a href=\"http:\/\/blogs.forbes.com\/sciencebiz\/2010\/06\/a-fix-for-the-avandia-mess\/?partner=yahootix\">A fix for the Avandia mess<\/a>&nbsp;(Harlan Krumholz on Forbes.com)<br \/>\n    <a href=\"http:\/\/www.theheart.org\/article\/1091901.do\">Another leaked rosiglitazone manuscript? Controversy spikes as&nbsp;<em>JAMA<\/em>,&nbsp;<em>Archives<\/em> publish new papers<\/a>&nbsp;(heartwire)<br \/>\n    <a href=\"http:\/\/www.theheart.org\/article\/1092925.do\">JUPITER gets a battering, but Ridker fights back<\/a>&nbsp;(heartwire)<br \/>\n    <a href=\"http:\/\/www.theheart.org\/article\/1093495.do\">New meta-analysis of statins in primary prevention does not suggest significant reduction in all-cause mortality <\/a>(heartwire)<br \/>\n    <a href=\"http:\/\/cardiobrief.org\/2010\/06\/29\/authors-of-jupiter-attack-are-members-of-obscure-anti-cholesterol-group\/\">Authors of JUPITER attack are members of obscure anti-cholesterol&nbsp;group<\/a>&nbsp;(CardioBrief)<br \/>\n    <a href=\"http:\/\/www.pharmalot.com\/2010\/06\/the-cholesterol-debate-and-journal-disclosures\/?utm_source=feedburner&amp;utm_medium=feed&amp;utm_campaign=Feed%3A+Pharmalot+%28Pharmalot%29\">The cholesterol debate and journal disclosures<\/a>&nbsp;(Pharmalot)<\/p>\n<p><strong><\/strong><strong><\/p>\n<p><\/strong><br \/>\n<strong><br \/>\nRetinopathy in ACCORD:<\/strong> In a paper presented at the American Diabetes Association and simultaneously <a href=\"http:\/\/content.nejm.org\/cgi\/content\/full\/NEJMoa1001288\">published online in the <em>New England Journal of Medicine<\/em><\/a>, the ACCORD Study Group and the ACCORD Eye Study Group report findings of the ACCORD trials on the progression of diabetic retinopathy in a subset of 2856 ACCORD participants. At 4 years, the investigators found that intensive glycemic control and intensive combination treatment of dyslipidemia significantly slowed the progression of retinopathy, while intensive blood pressure control did not.<strong><\/strong><strong><\/p>\n<p><\/strong><\/p>\n<p>    Intensive glycemia therapy vs. standard therapy: 7.3% vs 10.4% (P=0.003)<br \/>\n    Fenofibrate vs. placebo: 6.5% vs 10.2% (P=0.006)<br \/>\n    Intensive blood-pressure therapy vs. standard therapy: 10.4% vs 8.8% (P=0.29)<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Responding to the News: It&#8217;s been an extraordinary week for cardiology news, with major papers and controversies about rosiglitazone, statins, JUPITER, and clopidogrel. Here are a few statements and news reports that you might want to know about:&nbsp; ACC\/AHA release clinical alert in response to FDA boxed warning about anti-platelet agent, clopidogrel&nbsp;(ACC\/AHA) New analyses report [&hellip;]<\/p>\n","protected":false},"author":196,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-1572","post","type-post","status-publish","format-standard","hentry","category-general"],"_links":{"self":[{"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/posts\/1572","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/users\/196"}],"replies":[{"embeddable":true,"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/comments?post=1572"}],"version-history":[{"count":0,"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/posts\/1572\/revisions"}],"wp:attachment":[{"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/media?parent=1572"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/categories?post=1572"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/tags?post=1572"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}